Welcome to our dedicated page for Estrella Immunopharma SEC filings (Ticker: ESLA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Estrella Immunopharma, Inc. (NASDAQ: ESLA) SEC filings page provides access to the company’s U.S. Securities and Exchange Commission disclosures, including Current Reports on Form 8-K and other documents related to its clinical, corporate, and capital markets activities. Estrella identifies itself as an emerging growth company, with common stock and publicly traded warrants (ESLAW) registered under Section 12(b) of the Exchange Act and listed on The Nasdaq Stock Market LLC.
Through its SEC filings, Estrella reports material events such as milestones in the STARLIGHT-1 Phase I/II clinical trial of EB103, a CD19-redirected ARTEMIS® T-cell therapy for relapsed or refractory B-cell non-Hodgkin’s lymphoma. For example, Form 8-K filings have furnished press releases announcing completion of dose cohorts, Data Safety Monitoring Board recommendations, and other clinical updates. Filings also document Nasdaq communications regarding the company’s compliance with minimum bid price and market value listing requirements, along with confirmations that these matters were later considered closed.
Estrella’s filings further describe its registered securities, including common stock with a par value per share and warrants exercisable for one share of common stock at a specified exercise price. Investors can review these documents to understand the structure of ESLA and ESLAW, as well as the company’s status as an emerging growth company and the implications for its reporting obligations.
On this page, Stock Titan surfaces Estrella’s SEC filings with AI-powered summaries that highlight key points from lengthy documents, helping readers quickly identify clinical trial disclosures, listing status updates, financing-related information, and board or governance changes. Real-time updates from the SEC’s EDGAR system, combined with AI explanations of forms such as 8-K and registration statements, can assist investors in interpreting how new filings relate to Estrella’s ARTEMIS® T-cell programs and overall corporate profile.
Estrella Immunopharma, Inc. filed an amended annual report to add detailed disclosures on board composition, executive compensation, ownership and auditor matters for the period ended December 31, 2025. The filing confirms a seven‑member board, three key committees, and independence status for several directors.
The amendment shows the CEO and CFO each earned salary of $250,962 in 2025, with prior equity awards under the 2023 Omnibus Incentive Plan. As of March 12, 2026, 42,665,228 common shares were outstanding and Eureka Therapeutics, Inc. beneficially owned about 59.3% of the stock, making Estrella a controlled company under Nasdaq rules.
Estrella Immunopharma’s Chief Financial Officer, Jiandong Xu, reported a series of open-market purchases of the company’s common stock. On October 7, 2025, he bought 1,000 shares at $1.33 per share, bringing his direct holdings to 265,488 shares.
Earlier, on September 11, 2025, Xu purchased 100 shares at $1.04 per share. On September 22, 2025, 1,000 shares were purchased at $1.16 per share and are held by his spouse, totaling 16,700 shares in that account. The filing states Xu disclaims beneficial ownership of the spouse-held shares for Section 16 and other purposes.
Estrella Immunopharma, Inc. files its annual report describing progress as a clinical-stage biopharmaceutical company developing ARTEMIS T‑cell therapies for cancers and autoimmune diseases. Its lead CD19‑directed candidate, EB103, completed the Phase I dose‑escalation portion of the STARLIGHT‑1 trial in relapsed/refractory B‑cell non‑Hodgkin lymphomas.
In Phase I (n=9), no treatment‑related serious adverse events were reported and all cytokine release syndrome events were Grade 1–2. The high‑dose cohort achieved a 100% complete response rate at Month 1 in all 5 evaluable patients, with responses remaining in remission as of January 28, 2026. An independent safety board recommended advancing to Phase II, and dosing has begun.
Estrella is also advancing dual‑target CD19/CD22 candidate EB104, preclinical autoimmune program EB201 for lupus, and a “mark and kill” solid‑tumor collaboration using CF33‑CD19t with Imugene. As of March 12, 2026, market value of non‑affiliate equity was $20,496,203 with 42,665,228 common shares outstanding.
Estrella Immunopharma, Inc. has registered up to 9,236,141 shares of common stock for resale by existing selling stockholders. These resale shares, including warrant shares and true-up and reset shares from prior financings, equal about 22.0% of outstanding common stock as of January 11, 2026, and Estrella will receive no proceeds from their sale.
The company is a clinical-stage T‑cell therapy developer, led by CD19‑directed candidate EB103, which has early Phase I data in B‑cell lymphomas but remains in development. Estrella reported net losses of $12.5 million for the nine months ended September 30, 2025 and had an accumulated deficit of about $36.4 million, with only $1.6 million in cash and cash equivalents as of that date, leading to substantial doubt about its ability to continue as a going concern.
Control is concentrated: Eureka Therapeutics, Inc. holds roughly 60.1% of outstanding common stock and voting power, making Estrella a Nasdaq “controlled company.” The prospectus highlights high risk from significant ongoing losses, the need for substantial additional funding, dependence on Eureka for manufacturing and key intellectual property, and the potential for resale-related stock overhang that could pressure the share price.
Estrella Immunopharma, Inc. filed Amendment No. 2 to its Form S-1 registration statement as an exhibits-only update. The amendment leaves the substantive disclosure in the registration statement unchanged and focuses on updating the list of exhibits.
The filing itemizes corporate documents such as the amended and restated charter and bylaws, various merger and financing agreements, equity incentive plans, employment agreements, and a warrant agreement, largely incorporated by reference from earlier filings. It also includes the legal opinion from Winston & Strawn LLP, consents from current and former auditors, XBRL-related exhibits, and powers of attorney.
The amendment is signed on behalf of Estrella Immunopharma by Chief Executive Officer Cheng Liu and lists the company’s principal officers and directors, confirming their authorization of the registration statement.
Estrella Immunopharma, Inc. is registering up to 9,236,141 shares of common stock for resale by existing selling stockholders, including shares already issued, contingent “true-up” and reset shares, and shares issuable upon exercise of warrants from recent private placements. The registered resale shares represent approximately 22.0% of total common stock outstanding as of January 11, 2026, creating potential stock overhang as these holders may sell over time.
Estrella will not receive proceeds from stockholder resales under this prospectus. A significant portion of the shares was or may be issued at effective prices below recent trading levels, which may incentivize sales at market prices. The company remains a clinical-stage, loss‑making cell therapy developer focused on its lead candidate EB103 for relapsed or refractory B‑cell malignancies, with an accumulated deficit of about $36.4 million as of September 30, 2025 and a disclosed need for substantial additional funding. Estrella is controlled by Eureka Therapeutics, which holds about 60.1% of the voting power.
Estrella Immunopharma, Inc. reported that on January 7, 2026 it received a notice from Nasdaq stating the company is not in compliance with Nasdaq Listing Rule 5620(a) because it has not held an annual meeting of shareholders within the required time period. The letter gives Estrella 45 calendar days to submit a plan to regain compliance.
The company plans to submit this compliance plan within the deadline and is currently planning to hold an annual shareholder meeting in April 2026. Estrella expects to discuss with Nasdaq whether this meeting will restore compliance or if additional actions will be required. The notice does not immediately affect the listing or trading of the company’s common stock or warrants on Nasdaq.
Estrella Immunopharma, Inc. entered into a securities purchase agreement for a registered direct offering and concurrent private placement that together generated approximately $8.0 million in gross proceeds. The company sold 4,063,290 shares of common stock and issued pre-funded warrants to purchase 1,000,000 shares of common stock at an exercise price of $0.00001 per share.
Each common share and each pre-funded warrant was paired with one and a half PIPE common warrants, with common units priced at $1.58 and pre-funded units at $1.57999. The PIPE common warrants are exercisable for up to 7,594,935 shares at $1.39 per share, are immediately exercisable, and expire five years after issuance, subject to a 4.99% or 9.99% ownership cap. The company plans to use net proceeds for general corporate purposes and working capital and agreed to register the resale of PIPE warrant shares under a future resale registration statement.
Estrella Immunopharma (ESLA) reported that it completed the second dose cohort in the Phase I portion of its STARLIGHT-1 Phase I/II clinical trial of EB103. The company announced the milestone via a press release dated November 3, 2025, which is furnished as Exhibit 99.1 to this report.